Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat

by Zacks Equity Research

Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.

BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View

by Zacks Equity Research

BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.

BioMarin Pharmaceutical (BMRN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 116.00% and 3.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Stock Moves -0.84%: What You Should Know

by Zacks Equity Research

BioMarin Pharmaceutical (BMRN) closed at $76.88 in the latest trading session, marking a -0.84% move from the prior day.

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q3 Earnings Expected to Decline

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq

by Zacks Equity Research

The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.

Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH

by Zacks Equity Research

Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.

Zacks.com featured highlights include: Vail, Las Vegas Sands, BioMarin and Allegiant

by Zacks Equity Research

Zacks.com featured highlights include: Vail, Las Vegas Sands, BioMarin and Allegiant

BioMarin Initiates Gene Therapy Study for Phenylketonuria

by Zacks Equity Research

BioMarin (BMRN), a leader in the phenylketonuria segment, initiates development of its first gene therapy for treating the rare genetic enzyme deficiency disorder.

Rimmi Singhi headshot

Stay Away From These 4 Toxic Stocks to Avoid Losses

by Rimmi Singhi

Investors who can figure out the overpriced toxic stocks and shun them at the right time are the ones that are likely to benefit.

Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN

by Zacks Equity Research

Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN

Rimmi Singhi headshot

These 4 Stocks Could Be Toxic for Your Portfolio

by Rimmi Singhi

Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.

BioMarin Pharmaceutical (BMRN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

BioMarin Pharmaceutical (BMRN) closed at $76 in the latest trading session, marking a +0.21% move from the prior day.

BioMarin (BMRN) Down 34.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates

by Zacks Equity Research

The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.

BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

by Zacks Equity Research

BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.

BioMarin Down on CRL From FDA for Hemophilia A Candidate

by Zacks Equity Research

BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.

BioMarin's MAA for Dwarfism Candidate Gets EMA Validation

by Zacks Equity Research

The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.

Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU

by Zacks Equity Research

Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

by Zacks Equity Research

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.